Neues vom Weltkongress der Nephrologie 2009 - Selektive VDR-Aktivierung und kardiorenales Syndrom - ein Paradigmenwechsel

doi:10.1055/s-0029-1237457

Dialyse aktuell, Table of Contents

Dialyse aktuell 2009; 13(6): 334-337
DOI: 10.1055/s-0029-1237457

Forum der Industrie

Neues vom Weltkongress der Nephrologie 2009 - Selektive VDR-Aktivierung und kardiorenales Syndrom - ein Paradigmenwechsel

Abstract

Full Text

References

Literatur

01 Brown AJ . Finch J . Slatopolsky E . Differential effects of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on intestinal calcium and phosphorus transport. J Lab Clin Med. 2002; 139 279-284
02 Cardús A . Panizo S . Parisi E . et al . Differential effects of vitamin D analogues on vascular calcification. JBMR. 2007; 22 860-866
03 Bodyak N . Ayus JC . Achinger S . et al . Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA. 2007; 104 16810-16815
04 Agarwal R . Acharya M . Tian J . et al . Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005; 68 2823-2828
05 Alborzi P . Patel NA . Peterson C . et al . Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension. 2008; 52 249-255
06 Tan X . Li Y . Liu Y . Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol. 2006; 17 3382-3393
07 Husain K . Ferder L . Mizobuchi M . et al . Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am J Nephrol. 2009; 29 465-472
08 Ronco C . Haapio M . House AA . et al . Cardiorenal syndrome. J Am Coll Cardiol. 2008; 52 1527-1539
09 Resnick LM . Müller FB . Laragh JH . et al . Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med. 1986; 105 649-654
10 Freundlich M . Quiroz Y . Zhang Z . et al . Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 2008; 74 1394-1402
11 Zhang Z . Zhang Y . Ning G . et al . Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA. 2008; 105 15896-15901
12 Repo JM . Rantala IS . Honkanen TT . et al . Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. Kidney Int. 2007; 72 977-984
13 Matias PJ . Ferreira C . Jorge C . et al . 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrol Dial Transplant. 2009; 24 611-618
14 Wu-Wong JR . Nakane M . Ma J . et al . Elevated phosphorus modulates vitamin D receptor-mediated gene expression in human vascular smooth muscle cells. Am J Physiol Renal Physiol. 2007; 293 F1592-F1604
15 Teng M . Wolf M . Lowrie E . et al . Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Eng J Med. 2003; 349 446-456
16 Lambers Heerspink HJ . Agarwal R . Coyne DW . et al . The Selective Vitamin D Receptor Activator for Albuminuria Lowering (VITAL) study: Study design and baseline characteristics. Am J Nephrol. 2009; 30 280-286